Asset profile
Carfilzomib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
63 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Carfilzomib: this drug | Approved | Small molecule | Proteasome | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Ixazomib | Approved | Small molecule | Proteasome | ||
| TQB3602 | Phase 1 | Small molecule | Proteasome | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Melphalan Flufenamide | Approved | Small molecule | DNA (alkylation), delivered via aminopeptidase-mediated intracellular activation | ||
| Melphalan Hydrochloride (Evomela) | Approved | Small molecule | DNA (guanine N7 position) |
…and 48 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(49 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (7)
October 2026 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-10-20 · NCT06140966 · CT.gov ↗
What to watch
November 2026 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
Phase 1Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Recruiting
Est. primary completion 2026-11-24 · NCT06249282 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
December 2026 (3)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-28 · NCT03729804 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04883242 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT01863550 · CT.gov ↗
What to watch
2027 (22)
January 2027 (1)
Phase 2Plasma Cell Myeloma RefractoryRecruiting
Est. primary completion 2027-01-08 · NCT06356571 · CT.gov ↗
What to watch
February 2027 (2)
April 2027 (2)
May 2027 (2)
June 2027 (4)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT01297764 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT02899052 · CT.gov ↗
What to watch
Phase 1Kidney Transplant RejectionRecruiting
Est. primary completion 2027-06-30 · NCT06918990 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-06-30 · NCT05909826 · CT.gov ↗
What to watch
July 2027 (2)
August 2027 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT03909412 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-01 · NCT04096066 · CT.gov ↗
What to watch
October 2027 (2)
November 2027 (2)
December 2027 (3)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05651932 · CT.gov ↗
What to watch
2028 (9)
January 2028 (1)
Phase 2POEMS SyndromeRecruiting
Est. primary completion 2028-01 · NCT07652879 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
March 2028 (2)
May 2028 (1)
Phase 2Waldenstrom MacroglobulinemiaActive not recruiting
Est. primary completion 2028-05 · NCT04263480 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-07-01 · NCT05789303 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2028-08 · NCT05434689 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Plasma Cell MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07709884 · CT.gov ↗
What to watch
2029 (7)
January 2029 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-02 · NCT07348393 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-03-01 · NCT05896228 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2029-04 · NCT04822337 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-08 · NCT03948035 · CT.gov ↗
What to watch
December 2029 (1)
Phase 1Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, NeoplasmNot yet recruiting
Est. primary completion 2029-12-31 · NCT07715903 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-08-30 · NCT07227311 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2031-06-01 · NCT04513639 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗
What to watch
2035 (1)
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.